knowledge -WSS

knowledge

author：focus 2025-09-05 13:47:53 - browse：36

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： In new study, freeze

focus

WSS

7 of the most gruesome medical devices in history

Hilary expected to bring catastrophic, life

Beware the threat of staffing cuts at the CDC

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Why an extreme heat and wildfire smoke combination can be so dangerous

knowledge

knowledge

focus

Novavax promises a turnaround & Lilly roils the obesity market

CDC backtracks, saying fully vaccinated people can go maskless indoors

Medical records are filled with copy

Organ transplantation is at a crossroads. Major reform is needed

Duchenne breakthrough therapy leaves behind pioneering families

Caitlin Bernard's story shows physicians can't shy from advocacy

State Dept. review finds Biden bears some blame for Afghanistan failures

Elizabeth Warren probes abortion access

The high cost of giving birth even with insurance

Patient advocates sound warning on FDA proposal on salt intake

focus

Congress must give Medicare recipients genetic counseling access

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Cancer drug shortages' outsize impact on ovarian cancer patients

Our daughter's deadly disease: trisomy 18. We wanted to protect her

leisure time

focus

focus

leisure time